Unicycive Therapeutics Statistics
Total Valuation
UNCY has a market cap or net worth of $140.67 million. The enterprise value is $79.92 million.
| Market Cap | 140.67M |
| Enterprise Value | 79.92M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
UNCY has 27.86 million shares outstanding. The number of shares has increased by 107.81% in one year.
| Current Share Class | 27.86M |
| Shares Outstanding | 27.86M |
| Shares Change (YoY) | +107.81% |
| Shares Change (QoQ) | +12.59% |
| Owned by Insiders (%) | 2.26% |
| Owned by Institutions (%) | 40.06% |
| Float | 27.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 2.69 |
| PB Ratio | 2.64 |
| P/TBV Ratio | 2.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.81 |
| Quick Ratio | 3.28 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -571.17 |
Financial Efficiency
Return on equity (ROE) is -101.07% and return on invested capital (ROIC) is -58.51%.
| Return on Equity (ROE) | -101.07% |
| Return on Assets (ROA) | -40.59% |
| Return on Invested Capital (ROIC) | -58.51% |
| Return on Capital Employed (ROCE) | -62.12% |
| Weighted Average Cost of Capital (WACC) | 14.01% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.60M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.53% in the last 52 weeks. The beta is 1.78, so UNCY's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | +20.53% |
| 50-Day Moving Average | 5.54 |
| 200-Day Moving Average | 6.43 |
| Relative Strength Index (RSI) | 41.09 |
| Average Volume (20 Days) | 714,096 |
Short Selling Information
The latest short interest is 4.15 million, so 14.91% of the outstanding shares have been sold short.
| Short Interest | 4.15M |
| Short Previous Month | 4.33M |
| Short % of Shares Out | 14.91% |
| Short % of Float | 15.25% |
| Short Ratio (days to cover) | 5.09 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.13M |
| Pretax Income | -35.22M |
| Net Income | -35.22M |
| EBITDA | -33.09M |
| EBIT | -33.13M |
| Earnings Per Share (EPS) | -$1.56 |
Balance Sheet
The company has $61.43 million in cash and $671,000 in debt, with a net cash position of $60.75 million or $2.18 per share.
| Cash & Cash Equivalents | 61.43M |
| Total Debt | 671,000 |
| Net Cash | 60.75M |
| Net Cash Per Share | $2.18 |
| Equity (Book Value) | 53.27M |
| Book Value Per Share | 1.91 |
| Working Capital | 52.62M |
Cash Flow
In the last 12 months, operating cash flow was -$27.84 million and capital expenditures -$9,000, giving a free cash flow of -$27.85 million.
| Operating Cash Flow | -27.84M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 34,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -27.85M |
| FCF Per Share | -$1.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
UNCY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -107.81% |
| Shareholder Yield | -107.81% |
| Earnings Yield | -25.04% |
| FCF Yield | -19.80% |
Analyst Forecast
The average price target for UNCY is $28.22, which is 458.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.22 |
| Price Target Difference | 458.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 20, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jun 20, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |